Laura Brege - 04 Jun 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: Director
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 04 Jun 2025
Net transactions value: -$314,634
Form type: 4
Filing time: 05 Jun 2025, 18:01:14 UTC
Previous filing: 02 Jun 2025
Next filing: 13 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Brege Laura	Director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO	/s/ Jennifer J. Rhodes, Attorney-in-Fact	05 Jun 2025	0001365619

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Sale	$314,634	-14,446	-49%	$21.78	15,095	04 Jun 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.77 through $21.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.77 through $21.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.